Understand why more data doesn't mean safer programs — and what actually drives defensible nonclinical decisions.
Learn how CRO relationships, regulatory myths, and over-collection quietly derail programs — and how to recognize it before it's too late.
Build the judgment to own risk, sequence decisions strategically, and communicate a coherent safety narrative to regulators and leadership.
About Data Is Not Strategy
Data Is Not Strategy challenges one of the most deeply held assumptions in nonclinical drug development — that more data means safer programs. In this book, Dessi McEntee, MS, DABT lays out why interpretation, not volume, drives defensible nonclinical decisions, and what it actually looks like when strategy is working. By the end, you'll have the framework to own risk, lead with judgment, and build a safety narrative that holds up under regulatory scrutiny.
About the Author
Hi, I'm Dessi McEntee, MS, DABT — a board-certified toxicologist with over a decade of experience leading nonclinical programs across biotech and pharmaceutical development. I wrote this book after watching talented teams struggle not because of bad science, but because no one had given them a framework for turning data into decisions. My goal is simple: to give you the strategic clarity that typically takes senior professionals years to develop — so you can lead with confidence, defend your programs, and stop letting data substitute for judgment.
What People Are Saying
Discover how this digital download has helped professionals in the pharmaceutical industry excel in nonclinical drug development.
Coming from my own experience working in regulatory toxicology for many years, I found this book to be a clear reflection of real-world practice. Desi does an excellent job cutting through complexity and focusing on how safety questions are actually evaluated in regulated development environments. The writing is concise, practical, and grounded in experience, making it easy to absorb and immediately relevant. I would recommend this book to toxicologists looking for an efficient, experience-based perspective from someone who has clearly spent years doing the work.
Pharma Exec
A very reassuring approach to de-risking drug development and written with great clarity. The case studies were poignant. Well done.
Industry CEO
A clear-eyed take on nonclinical strategy that most teams learn too late This is not a textbook and it’s not a checklist - and that’s exactly why it’s valuable. What I appreciated most is what the book doesn’t do. It doesn’t promise certainty, oversell volume, or hide behind templates. Instead, it challenges teams to think critically about what their data means, what truly matters to regulators, and where responsibility for decisions really sits. This is a concise but substantive read for founders, development leaders, and scientists responsible for nonclinical direction - especially those navigating IND-enabling programs without deep internal toxicology leadership. Highly recommended for anyone who has ever felt that they had “enough data” but not enough clarity.
Biotech Scientist
Ready to Lead With Judgment?
Most programs have enough data. What they're missing is a framework for knowing what it means. For $9.99, get the book that changes how you think about nonclinical strategy — permanently.
$9.99